LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid COVID-19 Test Compares Solidly With PCR Detection in Largest Field Hospital Study

By LabMedica International staff writers
Posted on 08 Dec 2021
Print article
Image: Field hospital at Baltimore Convention Center (Photo courtesy of M.E. Newman, Johns Hopkins Medicine)
Image: Field hospital at Baltimore Convention Center (Photo courtesy of M.E. Newman, Johns Hopkins Medicine)

In what is believed to be the largest prospective study of its kind to date, researchers have reported that a rapid antigen detection test for SARS-CoV-2 proved more effective than expected when compared with virus detection rates using the established standard test, the polymerase chain reaction (PCR) assay.

The study by researchers at Johns Hopkins Medicine (Baltimore, MD, USA) and collaborators involved some 6,000 patients seen at the Baltimore Convention Center Field Hospital (BCCFH) during a 10-day period around the beginning of 2021. The first step for both the PCR and rapid antigen tests is obtaining a sample from a patient, either a nasal swab or a bit of saliva. The difference lies in how the sample is processed and analyzed. A PCR test takes a tiny bit of SARS-CoV-2 genetic material from a sample and reproduces it thousands of times so it can be more easily detected. A rapid antigen test uses laboratory-produced antibodies to seek out and latch onto proteins on the surface of SARS-CoV-2 particles in the sample.

The PCR test requires a skilled laboratory technician, special equipment and up to an hour or more to process. Additionally, testing on a massive scale can only be conducted at a large, centralized testing facility, such as a hospital laboratory. On the other hand, rapid antigen testing uses a premade kit with a reagent that contains antibodies specific for SARS-CoV-2. The test can be conducted by anyone after brief training, can be administered anywhere and provides results in approximately 15 minutes. The question that the new study hoped to answer was which test could be most broadly, most quickly and most effectively applied to a large community.

To do this, the researchers administered both the rapid antigen and PCR detection methods to just over 6,000 people who came to the Baltimore field hospital for COVID testing between Dec. 23, 2020, and Jan. 11, 2021. Participants were screened for possible exposure to the coronavirus and COVID-19 symptoms. Staff members performing the tests were trained exactly the same and monitored during test administration to ensure quality control and reliable results.

“We found that virus was accurately detected by the rapid antigen test in 87% of patients with COVID-19 symptoms and in 71% of those who were asymptomatic - rates that surprised us because they were so high,” said study lead author Zishan Siddiqui, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine. “This is a significant finding because the rapid test offers a number of advantages over the PCR test, including time savings, both in sampling and processing; cost savings; and most importantly, ease of distribution and application - basically anywhere - which can help overcome COVID testing disparities in medically underserved communities.”

“What we determined was that while the PCR test may be a better test from a clinical perspective - as it’s basically 100% accurate at detecting SARS-CoV-2 - the rapid antigen test appears to be better from a public health standpoint because of its ease of use, and the fact that it proved to have sufficient accuracy, specificity and reliability for detecting the coronavirus in a high-volume setting,” said study senior author James Ficke, M.D., professor of orthopedic surgery at the Johns Hopkins University School of Medicine and co-director of the BCCFH for 16 months. “The field hospital was the perfect place to determine this because we could see how well both tests worked for a large number of people in a short amount of time.”

Related Links:
Johns Hopkins Medicine 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more